HDAC INHIBITORS Russian patent published in 2018 - IPC C07D231/56 C07D401/06 C07D403/06 A61K31/416 A61K31/4439 A61P25/00 

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein R₁-X is attached to only one of the ring nitrogen atoms. X is -Y-[C(R^a)₂]_a-, where Y is a bond; R^a is H; a is 1, 2 or 3. R₁ is: (i) a monocyclic bicyclic heteroaryl having 5 to 6 ring atoms, which is optionally substituted with 1 to 3 R^o; wherein 1-2 ring atoms are a heteroatom independently selected from N and N-R^o; (ii) phenyl which is optionally substituted 1-3 R^o; or (iii) C₃-C₁₀ cycloalkyl. R₄ is H. Each variant of R^o is independently selected from the group consisting of halogen; C₁-C₆ alkyl and fluoro(C₁-C₆)alkyl. R₅ is hydrogen, R₂ is H and R₃ is H, F or Cl. Invention also relates to a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, methods for inhibiting said enzymes using a compound of formula (I) and methods for treating diseases mediated by said enzymes. (I).

EFFECT: compound of formula (I) inhibits histone deacetylase (HDAC) enzymes, for example HDAC1, HDAC2 and HDAC3.

40 cl, 5 tbl, 1 ex